Neuralstem, Inc. (NYSEMKT:CUR) Down 3.12%, TransAtlantic Petroleum Ltd (NYSEMKT:TAT) Down 2.46%
Northern, WI 05/20/2013 (GDPInsider) – Neuralstem, Inc. is down 3.12% after starting the day at 1.56. The stock had closed previously at 1.49 and has a range of 1.42 and 1.56. Volume is 791.38K, an increase of 92.05% on average volume of 412.05K.
CUR is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs. The company recently announced that principal investigator for the company, Eva Feldman, MD, PhD, had presented updated data from its Phase I spinal cord-derived human neural stem cell (NSI-566) trial in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) at the neuro diabetes special medical symposium in Bucharest, Romania.
CUR has been seeing an upward trend in its technical charts and the stock has been climbing northwards since the start of May 2012. CUR has a target price of 2.13 and at current valuation is trading 242.86% above its 52-week low of 0.42. The stock has a RSI of 64.97 and is trading 14.83% above its 20-day simple moving average.
Is CUR a solid investment at these levels? Get exclusive data and trends here.
TransAtlantic Petroleum Ltd (NYSEMKT:TAT) is down 2.46% after starting the day’s trading at 0.81. The stock had closed previously at 0.84 and has a range for the day at 0.8036 and 0.8252. Volume is 110.92K, down on average volume of 402.15K by 72.41%. At current market valuation TAT is trading 32.50% below its 52-week high of 1.20 and 14.08% above its 52-week low of 0.71.
TAT recently released preliminary Q1 2013 results in which the company disclosed expected total revenues to be between approximately $33.0 million and $37.0 million. TAT projected a net loss for the quarter of around $2.0 million and net income of around $6.0 million. The company did stress also that the results subject to change and that such changes may even be material changes.
TAT is down 1.64% on its SMA20 and 8.99% on its SMA50. Analysts have set a target of 1.41 and the RSI is presently 44.64. EPS this year is expected to rise 92.04% and the company has a market cap of $309.88 million.
How Should Investors Trade TAT Now? Get exclusive insights and updates here.
WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.